SUPERNUS PHARMACEUTICALS, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$3.74 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-03
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was -$3.79M.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was $49.00K, a 98.76% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was -$491.00K.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was -$21.53M.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was -$24.57M.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was -$15.02M.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was -$36.29M.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was -$19.16M, a 205.41% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$3.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$3.74M 10-Q · filed 2026-08-03 | -$4.23M derived: sum of 3 quarters · filed 2026-08-03 | -$25.76M derived: sum of 4 quarters · filed 2026-08-03 | |||
| 2026-03-31 | $49.00K 10-Q · filed 2026-05-05 | -$442.00K derived: sum of 2 quarters · filed 2026-05-05 | -$21.97M derived: sum of 3 quarters · filed 2026-05-05 | -$28.45M derived: sum of 4 quarters · filed 2026-08-03 | |||
| 2025-12-31 | -$491.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$22.02M derived: sum of 2 quarters · filed 2026-03-02 | -$28.50M derived: sum of 3 quarters · filed 2026-08-03 | -$24.57M 10-K · filed 2026-03-02 | |||
| 2025-09-30 | -$21.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$28.01M derived: sum of 2 quarters · filed 2026-08-03 | -$24.07M 10-Q · filed 2025-11-06 | -$24.49M derived: sum of 4 quarters · filed 2026-08-03 | |||
| 2025-06-30 | -$6.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$2.55M 10-Q · filed 2026-08-03 | -$2.96M derived: sum of 3 quarters · filed 2026-08-03 | -$14.79M derived: sum of 4 quarters · filed 2026-08-03 | |||
| 2025-03-31 | $3.94M 10-Q · filed 2026-05-05 | $3.52M derived: sum of 2 quarters · filed 2026-05-05 | -$8.31M derived: sum of 3 quarters · filed 2026-05-05 | -$21.10M derived: sum of 4 quarters · filed 2026-05-05 | |||
| 2024-12-31 | -$418.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$12.24M derived: sum of 2 quarters · filed 2026-03-02 | -$25.03M derived: sum of 3 quarters · filed 2026-03-02 | -$15.02M 10-K · filed 2026-03-02 | |||
| 2024-09-30 | -$11.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$24.62M derived: sum of 2 quarters · filed 2025-11-06 | -$14.60M 10-Q · filed 2025-11-06 | -$14.87M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2024-06-30 | -$12.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$2.77M 10-Q · filed 2025-08-05 | -$3.04M derived: sum of 3 quarters · filed 2026-03-02 | -$9.13M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2024-03-31 | $10.02M 10-Q · filed 2025-05-06 | $9.75M derived: sum of 2 quarters · filed 2026-03-02 | $3.66M derived: sum of 3 quarters · filed 2026-03-02 | -$15.72M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2023-12-31 | -$269.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$6.36M derived: sum of 2 quarters · filed 2026-03-02 | -$25.74M derived: sum of 3 quarters · filed 2026-03-02 | -$36.29M 10-K · filed 2026-03-02 | |||
| 2023-09-30 | -$6.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | -$25.47M derived: sum of 2 quarters · filed 2024-11-04 | -$36.02M 10-Q · filed 2024-11-04 | -$42.52M derived: sum of 4 quarters · filed 2025-02-25 | |||
| 2023-06-30 | -$19.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$29.93M 10-Q · filed 2024-08-06 | -$36.44M derived: sum of 3 quarters · filed 2025-02-25 | -$60.86M derived: sum of 4 quarters · filed 2025-02-25 | |||
| 2023-03-31 | -$10.55M 10-Q · filed 2024-05-08 | -$17.05M derived: sum of 2 quarters · filed 2025-02-25 | -$41.47M derived: sum of 3 quarters · filed 2025-02-25 | -$232.00K derived: sum of 4 quarters · filed 2025-02-25 | |||
| 2022-12-31 | -$6.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$30.93M derived: sum of 2 quarters · filed 2025-02-25 | $10.32M derived: sum of 3 quarters · filed 2025-02-25 | -$19.16M 10-K · filed 2025-02-25 | |||
| 2022-09-30 | -$24.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $16.82M derived: sum of 2 quarters · filed 2023-11-08 | -$12.66M 10-Q · filed 2023-11-08 | $21.25M derived: sum of 4 quarters · filed 2023-11-08 | |||
| 2022-06-30 | $41.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $11.76M 10-Q · filed 2023-08-08 | $45.67M derived: sum of 3 quarters · filed 2023-08-08 | $35.62M derived: sum of 4 quarters · filed 2023-08-08 | |||
| 2022-03-31 | -$29.48M 10-Q · filed 2023-05-09 | $4.43M derived: sum of 2 quarters · filed 2023-05-09 | -$5.62M derived: sum of 3 quarters · filed 2023-05-09 | -$1.29M derived: sum of 4 quarters · filed 2023-05-09 | |||
| 2021-12-31 | $33.91M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $23.86M derived: sum of 2 quarters · filed 2023-03-09 | $28.19M derived: sum of 3 quarters · filed 2023-03-09 | $18.18M 10-K · filed 2023-03-09 | |||
| 2021-09-30 | -$10.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$5.72M derived: sum of 2 quarters · filed 2022-11-09 | -$15.73M 10-Q · filed 2022-11-09 | -$8.31M derived: sum of 4 quarters · filed 2023-03-09 | |||
| 2021-06-30 | $4.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$5.68M 10-Q · filed 2022-08-08 | $1.74M derived: sum of 3 quarters · filed 2023-03-09 | -$21.34M derived: sum of 4 quarters · filed 2023-03-09 | |||
| 2021-03-31 | -$10.01M 10-Q · filed 2022-05-12 | -$2.59M derived: sum of 2 quarters · filed 2023-03-09 | -$25.67M derived: sum of 3 quarters · filed 2023-03-09 | $3.28M derived: sum of 4 quarters · filed 2023-03-09 | |||
| 2020-12-31 | $7.42M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$15.66M derived: sum of 2 quarters · filed 2023-03-09 | $13.29M derived: sum of 3 quarters · filed 2023-03-09 | $8.27M 10-K · filed 2023-03-09 | |||
| 2020-09-30 | -$23.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $5.87M derived: sum of 2 quarters · filed 2021-11-05 | $856.00K 10-Q · filed 2021-11-05 | ||||
| 2020-06-30 | $28.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $23.93M 10-Q · filed 2021-08-06 | |||||
| 2020-03-31 | -$5.02M 10-Q · filed 2021-05-07 | ||||||
| 2019-12-31 | -$11.68M 10-K · filed 2022-04-13 | ||||||
| 2018-12-31 | $4.12M 10-K · filed 2021-03-08 | ||||||
| 2014-09-30 | $2.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $7.33M derived: sum of 2 quarters · filed 2014-11-12 | $3.67M 10-Q · filed 2014-11-12 | $7.82M derived: sum of 4 quarters · filed 2014-11-12 | |||
| 2014-06-30 | $4.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-12 | $730.00K 10-Q · filed 2014-08-12 | $4.88M derived: sum of 3 quarters · filed 2014-08-12 | $7.88M derived: sum of 4 quarters · filed 2014-11-12 | |||
| 2014-03-31 | -$3.66M 10-Q · filed 2014-05-13 | $497.00K derived: sum of 2 quarters · filed 2014-05-13 | $3.50M derived: sum of 3 quarters · filed 2014-11-12 | $4.60M derived: sum of 4 quarters · filed 2014-11-12 | |||
| 2013-12-31 | $4.15M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-21 | $7.15M derived: sum of 2 quarters · filed 2014-11-12 | $8.25M derived: sum of 3 quarters · filed 2014-11-12 | $8.49M 10-K · filed 2014-03-21 | |||
| 2013-09-30 | $3.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $4.10M derived: sum of 2 quarters · filed 2014-11-12 | $4.34M 10-Q · filed 2014-11-12 | $2.48M derived: sum of 4 quarters · filed 2014-11-12 | |||
| 2013-06-30 | $1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-12 | $1.34M 10-Q · filed 2014-08-12 | -$518.00K derived: sum of 3 quarters · filed 2014-08-12 | $1.24M derived: sum of 4 quarters · filed 2014-08-12 | |||
| 2013-03-31 | $238.00K 10-Q · filed 2014-05-13 | -$1.62M derived: sum of 2 quarters · filed 2014-05-13 | $134.00K derived: sum of 3 quarters · filed 2014-05-13 | $394.00K derived: sum of 4 quarters · filed 2014-05-13 | |||
| 2012-12-31 | -$1.86M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-21 | -$104.00K derived: sum of 2 quarters · filed 2014-03-21 | $156.00K derived: sum of 3 quarters · filed 2014-03-21 | -$1.10M 10-K · filed 2014-03-21 | |||
| 2012-09-30 | $1.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-13 | $2.02M derived: sum of 2 quarters · filed 2013-11-13 | $761.00K 10-Q · filed 2013-11-13 | $660.00K 10-Q · filed 2012-11-02 | $2.27M derived: sum of 4 quarters · filed 2014-03-21 | ||
| 2012-06-30 | $260.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-14 | -$994.00K 10-Q · filed 2013-08-14 | -$1.11M 10-Q · filed 2012-08-13 | $518.00K derived: sum of 3 quarters · filed 2014-03-21 | -$1.24M derived: sum of 4 quarters · filed 2014-03-21 | ||
| 2012-03-31 | -$1.25M 10-Q · filed 2013-05-15 | -$1.39M 10-Q · filed 2012-06-08 | $258.00K derived: sum of 2 quarters · filed 2014-03-21 | -$1.50M derived: sum of 3 quarters · filed 2014-03-21 | -$1.37M derived: sum of 4 quarters · filed 2014-03-21 | ||
| 2011-12-31 | $1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-21 | -$244.00K derived: sum of 2 quarters · filed 2014-03-21 | -$113.00K derived: sum of 3 quarters · filed 2014-03-21 | -$959.00K 10-K · filed 2014-03-21 | |||
| 2011-09-30 | -$1.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-02 | -$1.63M derived: sum of 2 quarters · filed 2012-11-02 | -$2.47M 10-Q · filed 2012-11-02 | ||||
| 2011-06-30 | $131.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-13 | -$715.00K 10-Q · filed 2012-08-13 | |||||
| 2011-03-31 | -$846.00K 10-Q · filed 2012-06-08 | ||||||
| 2010-12-31 | $5.21M 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |